Is It Better To Be First Or Best? Daiichi Sankyo Shifts R&D Priorities
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Daiichi Sankyo's R&D leaders are optimistic about how factor Xa inhibitor edoxaban can compete in a potentially crowded market, but the company is also shifting its focus to development of first-in-class compounds, citing commercial and regulatory hurdles for follow-on, best-in-class products
You may also be interested in...
Daiichi Sankyo Gains First Approval For Oral Factor Xa Inhibitor In Japan
TOKYO - Daiichi Sankyo Co. Ltd. received official approval for the first oral Factor Xa inhibitor in Japan. Following a recommendation for approval in March, Japan's Ministry of Health, Labor and Welfare approved Lixiana (edoxaban) for prevention of post-surgery thromboembolism April 22
Daiichi Sankyo Gains First Approval For Oral Factor Xa Inhibitor In Japan
TOKYO - Daiichi Sankyo Co. Ltd. received official approval for the first oral Factor Xa inhibitor in Japan. Following a recommendation for approval in March, Japan's Ministry of Health, Labor and Welfare approved Lixiana (edoxaban) for prevention of post-surgery thromboembolism April 22
Daiichi Sankyo Gains First Approval For Oral Factor Xa Inhibitor In Japan
Boehringer Ingelheim's Pradaxa has set the bar by showing superiority to standard-of-care warfarin, and Daiichi Sankyo has staked a lot on an ongoing Phase III comparison study of Lixiana (edoxaban) to warfarin for the prevention of thromboembolism in atrial fibrillation, expected to report in 2012.